TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

MALVERN, Pa., Nov. 13, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors.

In a poster entitled "Phase 1 PK/PD Analysis of the Smac Mimetic TL32711 Demonstrates Potent and Sustained cIAP1 Suppression in Patient PBMC and Tumor Biopsies" (Abstract # A25), the degradation and suppression of cIAP1 was analyzed as part of the single agent Phase 1 study. The data demonstrated that TL32711 causes potent and sustained suppression of inhibitor of apoptosis protein cIAP1 in patient peripheral blood mononuclear cells (PBMCs) and tumor biopsies over 7 days at tolerable dose levels with evidence of apoptosis pathway activation and promising early signs of anti-tumor activity in patients.

In a poster entitled "Dose scheduling and efficacy analysis of the Smac mimetic TL32711 in primary melanoma tumor xenotransplant models" (Abstract # A225), tumor growth inhibition was observed in primary melanoma tumor xenografts following treatment with single agent TL32711.  Combining TL32711 with carboplatin and paclitaxel resulted in a further enhancement in anti-tumor efficacy with tumor regressions without any marked changes in tolerability.

About TL32711

TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies. TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors. In the clinical studies to date, TL32711 has been well tolerated and exhibited target suppression and antitumor activity.

About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.

Media Contact:

Russo Partners, LLC
Tony Russo, Ph.D., or Andreas Marathovouniotis
212-845-4251 or 212-845-5235
[email protected]
[email protected]

TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900

SOURCE TetraLogic Pharmaceuticals